Announcement • Apr 01
Petros Pharmaceuticals, Inc. announced delayed annual 10-K filing On 03/31/2026, Petros Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Announcement • Nov 08
Petros Pharmaceuticals, Inc. Announces Notice of Common Stock Delisting from Nasdaq On November 3, 2025, the Nasdaq Stock Market notified Petros Pharmaceuticals, Inc. that on November 7, 2025, it intended to announce the delisting of the Company’s common stock, par value $0.0001. The Common Stock was suspended from trading on The Nasdaq Capital Market on May 22, 2025, and has been trading on the OTCID® Basic Market (the “OTCID”) under the symbol “PTPI” since July 1, 2025. Nasdaq will file a Form 25 with the Securities and Exchange Commission to complete the delisting in accordance with Rule 12d2-2 promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which will deregister the Company’s Common Stock under Section 12(b) of the Exchange Act. The delisting will become effective ten days after the Form 25 is filed. The Common Stock will continue trading on the OTCID without disruption and the Company will remain subject to reporting obligations under Sections 13 and 15(d) of the Exchange Act. Announcement • May 27
Petros Pharmaceuticals, Inc.(OTCPK:PTPI) dropped from S&P TMI Index Petros Pharmaceuticals, Inc.(OTCPK:PTPI) dropped from S&P TMI Index